Cargando…
(123)I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations
Reduced uptake of (123)I- metaiodobenzylguanidine (MIBG) on cardiac gammagraphy and impaired odor identification are markers of neurodegenerative diseases with Lewy bodies (LB) as a pathological hallmark, such as idiopathic Parkinson’s disease (IPD). LRRK2 patients present with a clinical syndrome i...
Autores principales: | Valldeoriola, Francesc, Gaig, Carles, Muxí, Africa, Navales, Ignacio, Paredes, Pilar, Lomeña, Francisco, De la Cerda, Andres, Buongiorno, Mariateresa, Ezquerra, Mario, Santacruz, Pilar, Martí, Maria Jose, Tolosa, Eduardo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101340/ https://www.ncbi.nlm.nih.gov/pubmed/21221623 http://dx.doi.org/10.1007/s00415-010-5896-6 |
Ejemplares similares
-
Nonmotor Symptoms in LRRK2 G2019S Associated Parkinson’s Disease
por: Gaig, Carles, et al.
Publicado: (2014) -
Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers
por: Pont-Sunyer, Claustre, et al.
Publicado: (2015) -
(123)I-ioflupane brain SPECT and (123)I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders
por: Nuvoli, Susanna, et al.
Publicado: (2017) -
Transcriptome analysis in LRRK2 and idiopathic Parkinson’s disease at different glucose levels
por: Fernández-Santiago, Rubén, et al.
Publicado: (2021) -
Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout
por: Verberne, Hein J., et al.
Publicado: (2009)